Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint... This cohort study examines the association of KRAS status with outcomes following immune checkpoint inhibition monotherapy vs chemoimmunotherapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Loading next page...
 
/lp/american-medical-association/association-between-kras-variant-status-and-outcomes-with-first-line-vIRO8veAdY
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2021.0546
Publisher site
See Article on Publisher Site

Abstract

This cohort study examines the association of KRAS status with outcomes following immune checkpoint inhibition monotherapy vs chemoimmunotherapy.

Journal

JAMA OncologyAmerican Medical Association

Published: Jun 15, 2021

References